Camille Lobry
  • E-mail :[email]
  • Phone : +3361680001
  • Location : Paris, France
Last update 2022-09-12 15:55:15.288

Camille Lobry PhD, CRCN Inserm, Principal Investigator, team : Epigenetic regulations in AML leukemogenesis and resistance to treatment

Course and current status

Camille Lobry did his PhD in the laboratory of Pr Alain Israel at the Pasteur Institute in Paris. During his PhD he studied post translational modifications of the BCL10 protein involved in the regulation of NF-kB activity in T cells and identified a novel regulatory feedback loop in TCR-induced NF-kB activation. Impact of these results range from basic immunology to lymphoma transformation as BCL10 and NF-kB hyper-activation are involved in Mucosa Associated with Lymphoid Tissue lymphoma transformation

He then pursued his training by a postdoctoral fellowship in Pr Iannis Aifantis laboratory at New York University School of Medicine where he studied Notch signaling pathway in early hematopoiesis and myeloproliferative disorders. Using several novel in vivo genetic models of NOTCH inactivation and activation I was able to identify a new tumor suppressor role for this signaling pathway in myeloid hematological disorders. He also contributed to several seminal studies deciphering the role of important mutated genes in acute myeloid leukemia such as TET2 and SRSF2 and the role of Notch signaling in lymphoid differentiation and transformation.

In 2014 he started his own independent team at Gustave Roussy Cancer Center near Paris, France thanks to an ATIP-Avenir grant.

Since 2020 he is a Principal Investigator at the Saint Louis Research Institute (Inserm U944, Saint Louis Hospital, Paris, France)

 

Education and Diplomas

2019   Habilitation à Diriger des Recherches (HDR) (Université Paris Saclay, Orsay, France) 

2008   PhD in Molecular and Cellular Biology (Université Paris VII, Institut Pasteur, Paris, France)

2004   Master of Molecular and Cellular Biology (Université Paris VI, Paris, France)

 

Professional Experience

Since June 2020  Team leader, INSERM U944, Institut Jean Bernard, Hopital Saint Louis, Paris 

2014-2020  Team leader. ATIP-Avenir Team : Genetic and Epigenetic control of normal and malignant hematopoiesis (INSERM U1170)

2008-2014   Post-doctoral Fellow in Pr. Iannis Aifantis laboratory (NYU Medical School, New York USA)

2004-2008   PhD in Molecular and Cellular Biology (URA2582, Institut Pasteur, Paris, France)

 

Honors and Awards

2013  ATIP-Avenir laureate, CNRS-INSERM research support grant

2012  Postoctoral Fellowship, The Leukemia and Lymphoma Society Career Development Program Award

2011  NYU Kimmel Stem Cell Institute Post doctoral fellow of the year

2007  PhD fellowship, “Association pour la Recherche sur le Cancer” (ARC)

2006  Scholarship, Keystone symposium: NF-κB, 20 years on the road from biochemistry to pathology

2004  PhD fellowship, French “Ministère de la Recherche et de la Technologie”

2003  Fellowship of excellence, PARIS VI University


Scientific summary

Camille Lobry's laboratory focuses its activity on deciphering epigenetic mechanisms controlling gene expression in acute myeloid leukemia with a strong emphasis toward the study of non-coding genome such as long non-coding RNA and Super Enhancers. In order to study these mechanisms, his team uses combinations of molecular biology and genomic approaches (such as ChIP-seq, RNA-seq, ATAC-seq…) in cell lines and primary human cells as well as high throughput screening methods using CRISPRi and shRNA technologies. Using these approaches they recently identified a de novo Super Enhancer abnormally induced by ETO2-GLIS2 fusion in acute megakaryoblastic leukemia and responsible for KIT and PDGFRA overexpression and disease progression (Benbarche et al., 2022). In collaboration with the laboratory of Dr. Alexandre Puissant they characterized epigenetic and transcriptomic changes induced by folate deprivation or MTHFR polymorphisms and responsible for resistance to MYC-targeting therapies in acute myeloid leukemia (Su et al., 2020)

 

Selected Publications

1- Benbarche S, Lopez CK, Salataj E, Aid Z, Thirant C,Laiguillon MC, Lecourt S, Belloucif Y, Vaganay C, Antonini M, Hu J, da Silva Babinet A, Ndiaye-Lobry D, Pardieu B, Petit A,Puissant A, Chaumeil J, Mercher T and Lobry C. (2022) Screening of ETO2-GLIS2 induced Super Enhancers identifies targetable cooperative dependencies in acute megakaryoblastic leukemia. Sci Adv. 2022 Feb 9; 8(6):eabg9455. doi : 10.1126/sciadv.abg9455

2- Su A,Ling F, Vaganay C, Pardieu B, Benajiba L, Sodaro G, Pasanisi J, Lin KH, Rutter JC, Bassil CF, Antony-Debré I, Alexe G, Benoist JF, Pikman Y, Qi J, Dombret H, Preudhomme C, Fenouille N, Golan HM, Stegmaier K, Lobry C*, Wood KC*, Itzykson R* and Puissant A*. (2020) The folate cycle enzyme MTHFR is a critical regulator of cell response to MYC-targeting therapies. Cancer Discov 10(12):1894-1911, doi: 10.1158/2159-8290.CD-19-0970. *Co-last authors

3- Valls E*, Lobry C*, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SN, Oswald E, Graham CW, Jiang Y, Hatzi K, Agirre X, Perkey E, Li Z, Tam W, Bhatt K, Leonard JP, Zweidler-McKay PA, Maillard I, Elemento O, Ci W, Aifantis I, Melnick A (2017). BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer Discov. doi: 10.1158/2159-8290.CD-16-1189. *These authors contributed equally to the work

4- Thirant C, Ignacimouttou C, Lopez CK, Diop M, Le Mouël L, Thiollier C, Siret A, Dessen P, Aid Z, Rivière J, Rameau P, Lefebvre C, Khaled M, Leverger G, Ballerini P, Petit A, Raslova H, Carmichael CL, Kile BT, Soler E, Crispino JD, Wichmann C, Pflumio F, Schwaller J, Vainchenker W, Lobry C, Droin N, Bernard OA, Malinge S, Mercher T (2017). ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell. 31(3):452-465.

5- Lee SC, Dvinge H,Kim E, Cho H, Micol JB, Chung YR, Durham B, Yoshimi A, Kim YJ,Thomas M, Lobry C, Wang X, Krivtsov A, Armstrong SA, Palacino J, Buonamici S, Smith PG, Bradley RK, Abdel-Wahab O. (2016) Therapeutic targeting of myeloid leukemias with spliceosomal mutations through modulation of splicing catalysis. Nat Med. 22(6):672-8.

6- Oh P*, Lobry C*, Jie Gao J, Tikhonova A, Loizou E, Manet J, van Handel B, Ibrahim S, Greve J, Mikkola H, Artavanis-Tsakonas S and Aifantis I. (2013). In vivo Mapping of Notch Pathway Activity in Normal and Stress Hematopoiesis. Cell Stem Cell, 13(2): 190-204
*These authors contributed equally to the work

7- Lobry Cǂ, Ntziachristos P, Ndiaye-Lobry D, Oh P, Cimmino L, Zhu N, Araldi E, Hu W, Freund J, Abdel-Wahab O, Ibrahim S, Skokos D, Armstrong SA, Levine RL, Park CY, Aifantis Iǂ. (2013). Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med. 210(2): 301-19.
ǂ Co-corresponding authors

8- Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa M, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J Song C, Dai Q, He C, Ibrahim S, Beran M, Zavadil J, Nimer S, Melnick A, Godley LA, Aifantis I and Levine R. (2011) Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell, 20(1):11-24

9- Klinakis A*, Lobry C*, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E, Liu C, Ibrahim S, Beran M, Zavadil J, Efstratiadis A, Taghon T, Michor F, Levine RL and Aifantis I. (2011) A novel tumor suppressor function for the Notch pathway in myeloid leukemia. Nature, 473: 230-233
*These authors contributed equally to the work

10- Lobry C, Lopez T, Israel A and Weil R. (2007) Negative feedback loop in T cell activation through IkappaB kinase-induced phosphorylation and degradation of Bcl10. Proc Natl Acad Sci USA, 104, 908-913.


Pubmed

GoogleScholar

LinkedIn

Web of Science

ORCID

Image d’exemple